Atypical chemokine receptor CCRL2 is overexpressed in prostate cancer cells

Reyes, Niradiz; Benedetti, Inés; Rebollo, Juan; Correa, Óscar; Geliebter, Jan

doi:10.7555/jbr.32.20170057

Cited by 13 publications

(8 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Within the non-hematopoietic compartment, CCRL2 mRNA was detected in inflamed bronchial epithelium ( Oostendorp et al, 2004 ). Other reports described CCRL2 expression in hepatic stellate cells ( Zimny et al, 2017 ), in adipocytes ( Muruganandan et al, 2010 ), in skin ( Banas et al, 2015 ) and in different cancer tissues including breast ( Sarmadi et al, 2015 ) and prostate cancers ( Reyes et al, 2017 ). In primary human endothelial cells, either derived from umbilical veins, dermal microvascular or brain vasculature, CCRL2 was significantly upregulated by proinflammatory stimuli (e.g., the combination of LPS, IFN-γ, and TNF-α) ( Monnier et al, 2012 ).…”

Section: Regulation Of Ccrl2 Expressionmentioning

confidence: 99%

“…CCRL2 expression was described in different cancer cells, including prostate and breast carcinoma, colorectal cancer liver metastasis and glioblastoma ( Yin et al, 2012 ; Wang et al, 2015 ; Akram et al, 2016 ; Reyes et al, 2017 ). However, the functional role of CCRL2 in cancer is still unknown and needs further investigations.…”

Section: Role Of Ccrl2 In Tumorsmentioning

confidence: 99%

See 1 more Smart Citation

Molecular Basis for CCRL2 Regulation of Leukocyte Migration

Schioppa

Sozio

Barbazza

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

CCRL2 is a seven-transmembrane domain receptor that belongs to the chemokine receptor family. At difference from other members of this family, CCRL2 does not promote chemotaxis and shares structural features with atypical chemokine receptors (ACKRs). However, CCRL2 also differs from ACKRs since it does not bind chemokines and is devoid of scavenging functions. The only commonly recognized CCRL2 ligand is chemerin, a non-chemokine chemotactic protein. CCRL2 is expressed both by leukocytes and non-hematopoietic cells. The genetic ablation of CCRL2 has been instrumental to elucidate the role of this receptor as positive or negative regulator of inflammation. CCRL2 modulates leukocyte migration by two main mechanisms. First, when CCRL2 is expressed by barrier cells, such endothelial, and epithelial cells, it acts as a presenting molecule, contributing to the formation of a non-soluble chemotactic gradient for leukocytes expressing CMKLR1, the functional chemerin receptor. This mechanism was shown to be crucial in the induction of NK cell-dependent immune surveillance in lung cancer progression and metastasis. Second, by forming heterocomplexes with other chemokine receptors. For instance, CCRL2/CXCR2 heterodimers were shown to regulate the activation of β2-integrins in mouse neutrophils. This mini-review summarizes the current understanding of CCRL2 biology, based on experimental evidence obtained by the genetic deletion of this receptor in in vivo experimental models. Further studies are required to highlight the complex functional role of CCRL2 in different organs and pathological conditions.

show abstract

Section: Regulation Of Ccrl2 Expressionmentioning

confidence: 99%

Section: Role Of Ccrl2 In Tumorsmentioning

confidence: 99%

Molecular Basis for CCRL2 Regulation of Leukocyte Migration

Schioppa

Sozio

Barbazza

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…CCRL2 expression was also detected in colorectal cancer, where increased already in the early phase of liver colonization, what suggests involvement of the receptor in tumor metastatic processes [341]. In addition, CCRL2 is overexpressed in a metastatic prostate cancer cells and prostate cancer tissues from patients, both at the mRNA and protein level [342]. Moreover, CCRL2 showed cytoplasmic staining in examined cell line PC-3.…”

Section: Ccrl2/ackr5mentioning

confidence: 92%

The Role of Selected Chemokines and Their Receptors in the Development of Gliomas

Groblewska

Litman‐Zawadzka

Mroczko

2020

IJMS

View full text Add to dashboard Cite

Among heterogeneous primary tumors of the central nervous system (CNS), gliomas are the most frequent type, with glioblastoma multiforme (GBM) characterized with the worst prognosis. In their development, certain chemokine/receptor axes play important roles and promote proliferation, survival, metastasis, and neoangiogenesis. However, little is known about the significance of atypical receptors for chemokines (ACKRs) in these tumors. The objective of the study was to present the role of chemokines and their conventional and atypical receptors in CNS tumors. Therefore, we performed a thorough search for literature concerning our investigation via the PubMed database. We describe biological functions of chemokines/chemokine receptors from various groups and their significance in carcinogenesis, cancer-related inflammation, neo-angiogenesis, tumor growth, and metastasis. Furthermore, we discuss the role of chemokines in glioma development, with particular regard to their function in the transition from low-grade to high-grade tumors and angiogenic switch. We also depict various chemokine/receptor axes, such as CXCL8-CXCR1/2, CXCL12-CXCR4, CXCL16-CXCR6, CX3CL1-CX3CR1, CCL2-CCR2, and CCL5-CCR5 of special importance in gliomas, as well as atypical chemokine receptors ACKR1-4, CCRL2, and PITPMN3. Additionally, the diagnostic significance and usefulness of the measurement of some chemokines and their receptors in the blood and cerebrospinal fluid (CSF) of glioma patients is also presented.

show abstract

“…ACKRs typically bind chemokines without G protein signalling activation to promote ligand internalization and degradation; however, more importantly, they regulate immune functions by scavenging chemokines from the local environment. 32 Previous studies have demonstrated CCRL2 receptors to act as decoy receptors scavenging chemokines from the TME and their expression to be associated with poor dendritic cell trafficking. 33 Elevated CCRL2 expression has been shown in primary neutrophils relative to other immune cell types and further upregulated on neutrophil activation.…”

Section: Differential Tumour Immune Cell Infiltration Immune-related Differentially Expressed Genes Patient Outcomes In Cortisol-secretinmentioning

confidence: 99%

Integrative computational immunogenomic profiling of cortisol‐secreting adrenocortical carcinoma

Baechle

Hanna

Sekhar

et al. 2021

J Cellular Molecular Medi

View full text Add to dashboard Cite

Adrenocortical carcinoma (ACC) is among the rarest and most aggressive cancers. Although the current prognostication of patients with ACC primarily hinges on the presence or absence of metastases and tumour resectability, over a third of patients present with an advanced, unresectable disease. [1][2][3][4][5][6] Patients with fully resectable (R 0 ) disease have a reported 5-year survival rate of approximately 50%, whereas patients with the unresectable disease have a 5-year survival rate near 0% and a median survival of shorter than

show abstract

Atypical chemokine receptor CCRL2 is overexpressed in prostate cancer cells

Cited by 13 publications

References 38 publications

Molecular Basis for CCRL2 Regulation of Leukocyte Migration

Molecular Basis for CCRL2 Regulation of Leukocyte Migration

The Role of Selected Chemokines and Their Receptors in the Development of Gliomas

Integrative computational immunogenomic profiling of cortisol‐secreting adrenocortical carcinoma

Contact Info

Product

Resources

About